Business Context and Reporting Period
This Form 8-K reports on the 2010 annual meeting of stockholders for Nephros, Inc., held on January 10, 2011. The company is incorporated in Delaware with principal executive offices in River Edge, New Jersey.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and voting results.
Material Changes and Corporate Actions
- Board Election: Stockholders elected Lawrence J. Centella to the board of directors for a term expiring in 2013.
- Capital Structure Amendment: Stockholders approved an amendment to increase authorized capital stock from 95,000,000 to 905,000,000 shares and authorized common stock from 90,000,000 to 900,000,000 shares.
- Stock Incentive Plan: Stockholders approved an amendment to the 2004 Stock Incentive Plan, increasing reserved shares from 2,696,976 to 39,814,340.
- Reverse Stock Split: Stockholders approved a 1-for-20 reverse stock split of common stock. Concurrently, authorized capital stock was decreased back to 95,000,000 shares and authorized common stock to 90,000,000 shares.
- Auditor Ratification: Rothstein Kass & Company, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2010.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the voting results.
Investor Verification Checklist
- Verify the effective date and implementation details of the 1-for-20 reverse stock split.
- Confirm the updated number of authorized shares post-split (90,000,000 common shares).
- Review the impact of the increased share reserve (39,814,340 shares) on future dilution under the Stock Incentive Plan.
- Check subsequent filings for the official record date and trading adjustments related to the reverse split.